ION BLUE Encyclopedia

Syn-Ake

Syn-Ake is a cosmetic dipeptide (a synthetic waglerin-1 mimetic) marketed for expression lines; independent peptide-specific evidence is limited.

Evidence: Preclinical

Reading time:2 min
Citations:2
Updated:July 5, 2026

Type

Peptide

INCI Name

Synthetic cosmetic dipeptide (INCI Dipeptide Diaminobutyroyl Benzylamide Diacetate), a waglerin-1 mimetic

Direct Answer

Syn-Ake is a cosmetic dipeptide (a synthetic waglerin-1 mimetic) marketed for expression lines; independent peptide-specific evidence is limited.

Summary Table

Evidence Level

Preclinical

AI Summary

Syn-Ake (INCI Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a synthetic cosmetic dipeptide designed to mimic waglerin-1, a component of temple viper venom, and is marketed in the "neuro-cosmetic" category for expression lines. The evidence base is preclinical and limited: available studies include in silico and in vitro anti-aging assessments and multi-ingredient clinical cosmetic studies, rather than controlled trials isolating the peptide. It is a cosmetic ingredient, not an approved medicine, and marketed effects are not established for the peptide alone.

Key Information

Classification

1 Mechanisms

Key Takeaways

  • Syn-Ake is a cosmetic dipeptide (waglerin-1 mimetic) marketed for expression lines
  • Evidence is in silico, in vitro, or from multi-ingredient formulations
  • It is a cosmetic ingredient, not an approved medicine

Scientific Overview

In Plain English

Syn-Ake is a cosmetic peptide designed to imitate a component of snake venom (waglerin-1). It is marketed to relax expression lines. The available research includes computer modelling, lab tests, and studies of full cosmetic formulas rather than the peptide by itself. It is a cosmetic ingredient, not a medicine.

Scientific Details

Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a synthetic dipeptide marketed as a waglerin-1 mimetic proposed to antagonize the muscle nicotinic acetylcholine receptor, reducing expression-line appearance. Available literature includes in silico and in vitro anti-aging assessments and clinical studies of multi-ingredient serums containing the peptide; controlled trials isolating the peptide are limited.

How It Works

Syn-Ake is described as a waglerin-1 mimetic proposed to antagonize the muscle-type nicotinic acetylcholine receptor, an activity marketed as relaxing expression lines. This proposed mechanism is characterized in silico and in vitro and is not established by controlled human efficacy studies isolating the peptide.

Mechanism of Action

Proposed nicotinic acetylcholine receptor antagonism

cell

Marketed as a waglerin-1 mimetic proposed to antagonize the muscle nicotinic acetylcholine receptor; characterized in silico and in vitro, not established in controlled human efficacy studies isolating the peptide.

Evidence Level

Human Evidence

Human data come mainly from studies of multi-ingredient cosmetic serums containing the peptide, which do not isolate its individual effect.

Cell Evidence

In silico and in vitro studies describe proposed anti-aging activity.

Limitations

Controlled trials isolating the peptide are limited; marketed effects are not established for the peptide alone.

Why This Grade

Graded preclinical: evidence is in silico, in vitro, or from multi-ingredient formulations, without controlled human trials isolating the peptide.

References

  1. Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests. Journal of Biomolecular Structure & Dynamics.Cell / In Vitrodoi:10.1080/07391102.2023.2223681
  2. The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies. International Journal of Cosmetic Science.Human Studydoi:10.1111/ics.70087

Alternative Names

  • Dipeptide Diaminobutyroyl Benzylamide Diacetate
  • Waglerin-1 mimetic

Risks & Safety

  • Not a medicine; used as a cosmetic ingredient with the usual patch-test considerations
  • Independent evidence specific to the peptide is limited; marketed anti-aging effects are not established
  • Clinical data involve multi-ingredient formulations, so effects cannot be attributed to the peptide alone

Claim Boundaries

ION BLUE is an educational research aggregator. This content summarizes published scientific literature. It is not medically reviewed, is not medical advice, and is not a recommendation to use any substance. Consult a licensed healthcare provider. This entry summarizes limited cosmetic-ingredient research and is not an assertion that Syn-Ake produces any particular result.

This page summarizes published research and is for informational purposes only; it is not medical advice.